Stephens: Time To Buy Codexis (NASDAQ:CDXS)? Has $16.0000 Valuation Target

May 16, 2018 - By Michael Collier

Codexis, Inc. (NASDAQ:CDXS) Logo

Investors sentiment decreased to 2.17 in 2017 Q4. Its down 0.03, from 2.2 in 2017Q3. It worsened, as 3 investors sold Codexis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 27 raised stakes. 28.02 million shares or 9.42% more from 25.60 million shares in 2017Q3 were reported.

Parametric Port Assoc Limited Com, Washington-based fund reported 14,925 shares. Laurion Capital Management Ltd Partnership holds 0% or 59,726 shares. Deutsche Commercial Bank Ag holds 0% or 107,089 shares. Baillie Gifford And has 0.02% invested in Codexis, Inc. (NASDAQ:CDXS) for 1.84 million shares. Moreover, Wells Fargo Mn has 0% invested in Codexis, Inc. (NASDAQ:CDXS). Fmr Limited Co reported 0% stake. Telemark Asset Mngmt Ltd Limited Liability Company invested 5.32% in Codexis, Inc. (NASDAQ:CDXS). Savings Bank Of Montreal Can invested 0% in Codexis, Inc. (NASDAQ:CDXS). Ameritas invested 0% in Codexis, Inc. (NASDAQ:CDXS). Balyasny Asset Mgmt Limited Liability Corp stated it has 11,845 shares or 0% of all its holdings. Barclays Public Llc reported 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). California State Teachers Retirement Sys invested 0% in Codexis, Inc. (NASDAQ:CDXS). Perkins Capital Mgmt Inc has 0.24% invested in Codexis, Inc. (NASDAQ:CDXS). Credit Suisse Ag holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 11,766 shares. Northern reported 0% stake.

Since March 21, 2018, it had 0 insider buys, and 5 insider sales for $1.19 million activity. The insider Smith David V sold 6,000 shares worth $62,213. Shares for $124,683 were sold by KELLEY BERNARD J. 22,465 Codexis, Inc. (NASDAQ:CDXS) shares with value of $259,828 were sold by NICOLS JOHN J. WOLF DENNIS P sold $464,384 worth of stock.

Why Has Stephens Given Codexis (NASDAQ:CDXS) a $16.0000 Price Target

Research professionals at Stephens started coverage on shares of Codexis (NASDAQ:CDXS) in analysts report sent to investors on Wednesday morning. The financial company set Buy rating on the stock. Stephens’s target price per share of $16.0000 suggests potential of 14.70 % from the stock’s last stock close.

The stock increased 5.28% or $0.7 during the last trading session, reaching $13.95. About 602,084 shares traded or 43.64% up from the average. Codexis, Inc. (NASDAQ:CDXS) has risen 125.77% since May 17, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on August, 8. They expect $-0.03 EPS, up 76.92 % or $0.10 from last year’s $-0.13 per share. After $-0.10 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -70.00 % EPS growth.

Codexis, Inc. discovers, develops, and sells protein catalysts. The company has market cap of $742.70 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening. It currently has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

More important recent Codexis, Inc. (NASDAQ:CDXS) news were published by: which released: “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018, also published article titled: “Codexis Reports First Quarter 2018 Financial Results”, published: “Codexis to Hold First Quarter 2018 Conference Call on May 10” on May 03, 2018. More interesting news about Codexis, Inc. (NASDAQ:CDXS) was released by: and their article: “3 High-Growth Stocks That Are Just Getting Started” with publication date: May 12, 2018.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.